Introduction
============

Angiogenesis is an important factor that influences the development of atherosclerotic plaques and is closely associated with local neovascularization and plaque stability ([@b1-etm-0-0-6594]). It has been demonstrated that excessive angiogenesis is associated with intraplaque hemorrhage, suggesting that neovascularization may contribute to lesion progression and rupture ([@b2-etm-0-0-6594]). Rupture-prone vulnerable plaques exhibit high lipid infiltration, increased numbers of inflammatory cells, a thin fibrous cap, and extensive endometrial and adventitial neovascularization ([@b3-etm-0-0-6594]--[@b5-etm-0-0-6594]). Studies have generally focused on the intimal accumulation of lipids and inflammatory cells ([@b6-etm-0-0-6594],[@b7-etm-0-0-6594]); however, the results of a recent study suggest that endothelial cells also serve a critical role during advanced plaque angiogenesis ([@b8-etm-0-0-6594]).

LncRNAs are transcripts that are \>200 nucleotides long, which regulate transcription via chromatin modulation, post-transcriptional regulation, organization of protein complexes, cell signaling and allosteric regulation ([@b9-etm-0-0-6594],[@b10-etm-0-0-6594]). They serve important roles in physiological processes, including the differentiation, proliferation, apoptosis and invasion of induced pluripotent stem cells ([@b11-etm-0-0-6594],[@b12-etm-0-0-6594]). Studies have demonstrated that several lncRNAs, including lncRNA-p21 ([@b13-etm-0-0-6594]), metastasis associated lung adenocarcinoma transcript 1 ([@b14-etm-0-0-6594]) and lnc-Ang362 ([@b15-etm-0-0-6594]), are associated with the progression of atherosclerosis and relevant cellular processes. Furthermore, it has been confirmed that lncRNA is able to facilitate endothelial angiogenic function ([@b16-etm-0-0-6594]).

MicroRNAs (miRNAs) are endogenous small single-strand non-coding RNAs \~22 nucleotides long ([@b17-etm-0-0-6594]). Certain miRNAs are able to regulate angiogenic processes and negatively modulate angiogenesis ([@b18-etm-0-0-6594]). For example, miRs-221 and −222 are able to regulate the development and differentiation of endothelial cells (ECs) but suppress pro-angiogenic activation and migration ([@b19-etm-0-0-6594]). Furthermore, the EC-derived miRNA 17--92 cluster negatively regulates arteriogenesis via miRNA-19 repression of Wnt signaling ([@b20-etm-0-0-6594]). miR-21 is highly expressed in ECs and studies have demonstrated that miR-21 expression suppresses the expression of phosphatase and tensing homolog (PTEN) but upregulates vascular endothelial growth factor (VEGF) expression ([@b21-etm-0-0-6594]). Furthermore, miR-21 has been identified as a modulator of migration and tubulogenesis in HUVECs ([@b22-etm-0-0-6594]).

The present study measured the expression of lncRNAs in tumor necrosis factor (TNF)-α-induced HUVECs and demonstrated that TCONS_00024652 was overexpressed. Functional experiments indicated that TCONS_00024652 silencing leads to the inhibition of angiogenesis and the expression of downstream miR-21. It was therefore suggested that TCONS_00024652 silencing induces the subsequent upregulation of miR-21.

Materials and methods
=====================

### Cell culture

Human umbilical vein endothelial cells (HUVECs) were obtained from the American Type Culture Collection (cat. no. CRL-1730, Manassas, VA, America) and cultured in Dulbecco\'s modified Eagle\'s medium (DMEM; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) with 10% (v/v) fetal bovine serum (FBS; Hyclone; GE Healthcare, Logan, UT, USA) in a humidified incubator at 37°C with 5% CO~2~. HUVECs were seeded at 3×10^5^ cells/well in 6-well plates and treated with varying concentrations (0.5, 1 or 2 ng/ml for 24 h) or for varying times (1 ng/ml for 6, 12 or 24 h) with recombinant human TNF-α (Peprotech, Rock Hill, NJ, USA). Following treatment, cells were lysed and RNA or protein was extracted for further experiments.

### Cell transfection

All small interfering (si)RNAs used in the current study were synthesized by Shanghai GenePharma Co., Ltd. (Shanghai, China), including si-lncRNA, mimic siRNAs, inhibitor siRNAs and scramble negative control (NC) siRNAs. Cells at 70% confluence were transfected with 100 nM siRNAs using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.), following the manufacturer\'s protocol. The si-TCONS_00024652-1 sequences were: 5′-GUGAAUUCAACAGACUGAAUU-3′ and the si-TCONS_00024652-2 sequence was 5′-GUGAUUUACCAGUCAGUGAAU-3′. The sequences of miR-21 mimics, inhibitor and negative control were as follow: miR-21 mimics forward, 5′-UGGCAGUCUCUUAGAUGGUGG-3′ and reverse, 5′-GCCAUGCAAGACACUGCCAGG-3′; miR-21 inhibitor forward, 5′-UUCUAGCCUACACCGUCCCGAA-3′ and reverse, 5′-UGGUAGUCGACUCCGCACCTGA-3′; negative control forward: 5′-UUCUCGGAACGUGUCACGUTT-3′ and reverse: 5′-UUCAAGGCCCGUGUCAUGUGG-3′. Subsequent experiments were performed 48 h following transfection.

### Cell proliferation assay

EC proliferation was measured using a Cell Counting Kit-8 (CCK-8; Dojindo Molecular Technologies, Kuamoto, Japan). Following transfection, cells were seeded in 96-well plates at density of 5×10^3^/well. CCK-8 solution was added and cells were incubated at 37°C for 90 min. Subsequently, absorbance was measured using an Infinite 200 Pro microplate reader (Tecan Group Ltd., Mannedorf, Switzerland) at 450 nm.

### RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Total RNA was extracted from HUVECs using total RNA extraction reagent (Shanghai Genepharma, Co. Ltd.) and cDNA was synthesized from the extracted RNA using a FastQuant RT kit \[Tiangen Biotech (Beijing) Co., Ltd., Beijing, China\]. qPCR was then performed using SuperReal PreMix Plus \[Tiangen Biotech (Beijing), Co., Ltd., Beijing, China\]. GAPDH was used as an internal control. All primers were synthesized by Sangon Biotech Co., Ltd. (Shanghai, China). The sequences of the primers used were as follows: miR-21 stem-loop RT primer, 5′-CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGTCAACATC-3′; miR-21 forward, 5′-ACACTCCAGCTGGCTAGCTTATCAGACTGATG-3′ and reverse, 5′-CTCAACTGGTGTCGTGGA-3′; GAPDH forward, 5′-GTCAACGGATTTGGTCTGTATT-3′ and 5′-AGTCTTCTGGGTGGCAGTGAT-3′. Primer sequences for lncRNA are listed in [Table I](#tI-etm-0-0-6594){ref-type="table"}. Thermal cycling conditions were as follows: 94°C for 15 min; followed by 40 cycles of 94°C for 15 sec, 60°C for 32 sec, 72°C for 60 sec. Relative expression levels of gene were quantified based target gene/GAPDH and calculated using the 2^−ΔΔCq^ method ([@b23-etm-0-0-6594]).

### Bioinformatics analysis

RNA-RNA and protein-RNA interaction networks were analyzed using StarBase v2.0 (<http://starbase.sysu.edu.cn/>). The database contains unique features, including determination of ceRNA functional networks based on miRNA-target interactions, provides comprehensive miRNA-lncRNA interactions and drafts interaction maps between miRNAs and circRNAs ([@b24-etm-0-0-6594]).

### Luciferase assay

To examine interactions between TCONS_00024652 and miR-21, wild-type pmirGLO-TCONS_00024652 and diverse mutant pmirGLO-TCONS_00024652 with pmirGLO-promotor vector (GenePharma, Shanghai, China) were constructed. miR-21 mimics, mimic NC, miR-21 inhibitor and inhibitor NC were purchased from GenePharma Co., Ltd. (Shanghai, China), 293T cells were plated at a density of 8×10^3^ cells/well in 96-well plates and cultured at 37°C with 5% CO~2~ overnight. Cells were then co-transfected with the wild-type or mutant luciferase reporter plasmids, and miR-21 mimic or NC using Lipofectamine 2000. Following 48 h, luciferase activity was measured using the Bright-Glo^™^ Luciferase assay system (Promega Corporation, Madison, WI, USA) and normalized to that of *Renilla* luciferase.

### Wound healing assay

HUVECs at 80% confluence were plated at a density of 3×10^5^ cells/well in 6-well plates and cultivated in DMEM without FBS at 37°C overnight. The monolayer of HUVECs was scratched with a 1 ml of a 200 µl pipette tip to form wound gaps. Cells were washed by PBS and incubated with 1 ng/ml TNF-α at 37°C to induce cell migration for 24 h. Images were captured using light microscope (magnification, ×200). Cells were photographed prior to and 24 h following scratching and the migration distance were calculated by Image J 1.48 software (National Institutes of Health, Bethesda, MD, USA).

### Tube formation assay

A tube formation assay was performed to detect the angiogenesis ability of HUVECs. Briefly, cells were harvested following treatment and seeded into a 96-well plate (1×10^4^ cells/well) coated with 10 mg/ml Matrigel (BD Biosciences, Franklin Lakes, NJ, USA). Following 7 h incubation at 37°C, capillary tube structures were observed and representative images were captured using a light microscope (magnification, ×400). The branching length was determined using Image-Pro plus 6.0 (Media Cybernetics, Rockville, MD, USA).

### Statistical analysis

All statistical analyses were performed using GraphPad Prism 6.0 software (GraphPad, Software Inc., La Jolla, CA, USA) and SPSS version 19.0 (IBM Corp., Armonk, NY, USA). Unpaired Student\'s t test or one-way analysis of variance followed by least significant difference tests were performed to determine differences among groups. Heterogeneous data was analyzed using one-way analysis of variance followed by Dunnett\'s tests. All data are presented as the mean ± standard deviation and P\<0.05 was considered to indicate statistically significant difference.

Results
=======

### LncRNA expression profiles indicate that TCONS_00024652 is upregulated following TNF-α treatment in HUVECs

During the initial phase of the current study, HUVECs were stimulated with TNF-α and levels of lncRNAs associated with the regulation of vascular function ([@b25-etm-0-0-6594],[@b26-etm-0-0-6594]) and atherosclerosis ([@b27-etm-0-0-6594]) were assessed using RT-qPCR. The results revealed that expression of a majority of lncRNAs was significantly increased in these HUVECs following TNF-α treatment; TCONS_00024652 exhibited the largest changes ([Fig. 1A](#f1-etm-0-0-6594){ref-type="fig"}). Therefore, it was selected as the target lncRNA in subsequent experiments. RT-qPCR was performed to further validate the up-regulation of TCONS_00024652 following stimulation with TNF-α ([Fig. 1B and C](#f1-etm-0-0-6594){ref-type="fig"}). These results indicate that TNF-α treatment up-regulates the expression of TCONS_00024652 in a dose-dependent manner.

### TCONS_00024652 knockdown inhibits the proliferation, migration and angiogenesis of HUVECs

The function of TCONS_00024652 in cell proliferation and angiogenesis was investigated. To ensure the effectiveness of siRNAs in gene inhibition, two TCONS_00024652 siRNAs (si-TCONS_00024652-1 and si-TCONS_00024652-2) were designed and transfected into HUVECs to determine the effect of TCONS_00024652 on atherosclerosis progression. Transfection efficiency was determined using RT-qPCR and the results indicated that the transfection efficiency of si-TCONS_00024652-1 was higher than that of si-TCONS_0024652-2 ([Fig. 2A](#f2-etm-0-0-6594){ref-type="fig"}). Furthermore, the results of the CCK-8 assay indicated that si-TCONS_00024652-1 was more effective at reducing the proliferation of HUVECs compared with si-TCONS_00024652-2 ([Fig. 2B](#f2-etm-0-0-6594){ref-type="fig"}). Therefore, si-TCONS_00024652-1 alone was used in subsequent experiments. The results of the wound healing assay indicated that TCONS_00024652 silencing significantly decreased the migration of cells compared with the blank control ([Fig. 2C and D](#f2-etm-0-0-6594){ref-type="fig"}). Furthermore, TCONS_00024652 knockdown significantly reduced the ability of endothelial cells to form lumens ([Fig. 2E and F](#f2-etm-0-0-6594){ref-type="fig"}). Taken together, these results indicate that TCONS_00024652 promotes the proliferation and angiogenesis of endothelial cells.

### TCONS_00024652 directly targets miR-21

Previous studies have demonstrated that miR-21 possesses anti-proliferative ([@b28-etm-0-0-6594]) and anti-angiogenesis ([@b24-etm-0-0-6594],[@b29-etm-0-0-6594]) properties; therefore it was hypothesized that miR-21 may be a downstream target in TNF-α-induced HUVEC activation. Bioinformatics analysis indicated that miR-21 was a potential target of TCONS_00024652 ([Fig. 3A](#f3-etm-0-0-6594){ref-type="fig"}). To explore the effect of TCONS_00024652 on miR-21, its expression was measured in HUVECs following TCONS_00024652 knockdown. The results demonstrated that miR-21 expression was significantly increased compared with the blank control ([Fig. 3B](#f3-etm-0-0-6594){ref-type="fig"}). Furthermore, the expression of TCONS_00024652 was significantly decreased in HUVECs transfected with the miR-21 mimic ([Fig. 3C](#f3-etm-0-0-6594){ref-type="fig"}) and increased in cells transfected with the miR-21 inhibitor ([Fig. 3D](#f3-etm-0-0-6594){ref-type="fig"}). The results of the luciferase reporter assay confirmed that miR-21 interacts with TCONS_00024652, indicating that luciferase activity was significantly decreased following transfection of miR-21 into TCONS_0024652-WT ([Fig. 3E](#f3-etm-0-0-6594){ref-type="fig"}). Overall, these data indicate that TCONS_00024652 downregulates miR-21 expression.

### miR-21 inhibition reverses the inhibitory effect of TCONS_00024652 knockdown on proliferation, migration and angiogenesis in HUVECs

The aforementioned results demonstrated that there is an association between TCONS_00024652 and miR-21. Thus, it was hypothesized that miR-21 may neutralize the effects of TCONS_00024652 on HUVECs. A series of experiments were performed to confirm that TCONS_00024652 affects cell proliferation and angiogenesis by regulating miR-21 expression in endothelial cells. In cells stably transfected with si-TCONS_00024652, the expression of miR-21 was significantly higher than in the control group; this increase was reversed following transfection with miR-21 inhibitor ([Fig. 4A](#f4-etm-0-0-6594){ref-type="fig"}). The co-transfection of the miR-21 inhibitor significantly reversed the inhibitory effects of si-TCONS_00024652 on HUVEC proliferation, migration and invasion ([Fig. 4B-D](#f4-etm-0-0-6594){ref-type="fig"}). These results demonstrate that TCONS_00024652 affects endothelial cell proliferation and angiogenesis via the regulation of miR-21 expression, suggesting that TCONS_00024652 acts as a competing endogenous RNA (ceRNA) for miR-21.

Discussion
==========

Studies investigating the effects of inflammation on atherosclerotic plaques have tended to focus on their innate immune and adaptive immune responses. However, it has been demonstrated that inflammation is closely associated with neovascularization in plaques and that this may be another mechanism which increases the vulnerability of plaques ([@b30-etm-0-0-6594]). Chemokine and inflammatory factors secreted by plaque inflammatory cells are able to directly or indirectly promote angiogenesis; this process is referred to as 'inflammatory angiogenesis' ([@b31-etm-0-0-6594]). The biological effect of TNF-α depends on its concentration and the type of cell it is acting on. High concentrations of TNF-α activate tumor necrosis factor receptor (TNFR) 1 to induce inflammation and stimulate the apoptosis of endothelial cells; however low concentrations of TNF-α promote endothelial cell proliferation, migration and microvascular production via TNFR2 ([@b32-etm-0-0-6594]). The present study successfully used low concentrations of TNF-α to induce endothelial angiogenesis and also confirmed the important role that inflammation serves in angiogenesis.

Previous studies have demonstrated the critical role that lncRNAs serve during the progression of various diseases ([@b33-etm-0-0-6594],[@b34-etm-0-0-6594]), including cardiovascular disease ([@b35-etm-0-0-6594]). It has been demonstrated that smooth muscle and endothelial cell enriched migration/differentiation-associated lncRNA regulates endothelial cell differentiation and the angiogenic capacity of HUVEC ([@b36-etm-0-0-6594]). Furthermore, a conserved natural noncoding antisense RNA in the tie-1 locus lncRNA-myocardial infarction associated transcript serve important roles in the pathological mechanism of atherosclerosis and may function as molecular sponges in VECs ([@b37-etm-0-0-6594],[@b38-etm-0-0-6594]). In the present study, the gene expression profile of the lncRNA TCONS_00024652 was screened and its functional importance in TNF-α-induced HUVECs was determined. TCONS_00024652 silencing reduced the proliferation and angiogenesis of TNF-α-induced HUVECs, suggesting that TCONS_00024652 serves an angiogenesis-promoting role in TNF-α-stimulated HUVECs.

In addition to regulating transcription, it has been demonstrated that many lncRNAs function as endogenous decoys for miRNAs. For example, LOC100129973, an important regulator of endothelial cell apoptosis, contains sites that bind to miR-4707-5p and miR-4767 ([@b39-etm-0-0-6594]). XLOC_008466 functions as an oncogene in non-small cell lung cancer by regulating the miR-874-matrix metalloproteinase/X-linked inhibitor of apoptosis protein axis ([@b40-etm-0-0-6594]). In the present study, bioinformatics was used to search for target miRNAs to reveal the downstream regulatory pathway by which TCONS_00024652 acts on HUVECs. The results indicated that miR-21 directly targets TCONS_00024652. The rescue experiments and luciferase reporter assay confirmed that TCONS_00024652 and miR-21 had a pairing region. Furthermore, it was demonstrated that TCONS_00024652 targets miR-21, decreasing its expression, thus acting as a ceRNA or molecular sponge. This indicates that TCONS_00024652 induces the proliferation and angiogenesis of VECs and stimulates the formation of atherosclerotic plaques. Although the results of the present study clearly indicate that there is an interaction between miR-21 and TCONS_00024652 that results in the regulation of HUVEC proliferation and angiogenesis, their effects on downstream target proteins remains uncertain. The instability of atherosclerotic plaques is associated with immature angiogenesis and the regulation of the interaction between VEGF and other factors may result in the recruitment of pericytes and promotion of neovascularization by the basement membrane ([@b41-etm-0-0-6594]). Future studies are required to elucidate the mechanisms of action of TCONS_00024652 and miR-21 on atherosclerotic plaques.

In conclusion, the results of the current study indicate that the increased expression of the endothelium-associated lncRNA TCONS_00024652 promotes plaque angiogenesis and the progression of atherosclerosis via the TCONS_00024652/miR-21 signaling pathway, suggesting that TCONS_00024652 may be an important molecular marker that stabilizes atherosclerotic plaques and slows down the progression of atherosclerosis.
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lncRNA

:   long noncoding RNA

VECs

:   vascular endothelial cells
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:   tumor necrosis factor α
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:   human umbilical vein endothelial cells

PTEN

:   phosphatase and tensin homolog

TNFR1

:   tumor necrosis factor receptor 1

![The expression of TCONS_00024652 was significantly increased in TNF-α-induced HUVECs. (A) Following stimulation with TNF-α for 24 h, the relative expression profile of lncRNA in HUVECs was detected by reverse transcription-quantitative polymerase chain reaction. (B) Relative expression of TCONS_00024652 in HUVECs following treatment with different concentrations (0, 0.5, 1 and 2 ng/ml) of TNF-α. (C) Relative expression of TCONS_00024652 in HUVECs following treatment with 1 ng/ml TNF-α over different time periods (0, 6, 12 and 24 h). Data are presented as the mean ± standard deviation. \*P\<0.05 and \*\*P\<0.01 vs. control. HUVEC, human umbilical vein endothelial cells; TNF, tumor necrosis factor; lncRNA, long non-coding RNA.](etm-16-04-3309-g00){#f1-etm-0-0-6594}

![TCONS_00024652 promotes the proliferation, migration and angiogenesis of HUVECs *in vitro*. (A) The relative expression of TCONS_00024652 in HUVECs following transfection with si-NC, si-TCONS_00024652-1 or si-TCONS_00024652-2 was measured using reverse transcription-quantitative polymerase chain reaction. (B) A Cell Counting Kit-8 assay was used 24 h following transfection with si-TCONS_00024652-1 and si-TCONS_00024652-2 to determine the proliferation of HUVECs. (C) The migratory ability of HUVECs was detected using a wound-healing assay following transfection with si-TCONS_00024652-1 (magnification, ×200). (D) Histogram presenting relative migration distance. (E) Transfected HUVECs were seeded onto Matrigel and then allowed to form capillary-like structures for 7 h (magnification, ×400). (F) Statistical analysis of the length of tubular structures in each group. Data are presented as the mean ± standard deviation. \*P\<0.05 and \*\*P\<0.01 vs. control; ^\#\#^P\<0.01 vs. blank. Si, small interfering; HUVEC, human umbilical vein endothelial cells; TNF, tumor necrosis factor; OD, optical density.](etm-16-04-3309-g01){#f2-etm-0-0-6594}

![miR-21 is a direct target of TCONS_00024652 in HUVECs. (A) Putative complementary sites within miR-21 and the 3′-untranslated region of TCONS_00024652 were predicted using starBase. (B) Relative expression of miR-21 in HUVECs transfected with si-TCONS_00024652. (C and D) Relative expression of TCONS_00024652 mRNA levels following transfection with miR-21 mimic or inhibitor, as determined using reverse transcription-quantitative polymerase chain reaction. (E) Luciferase activity in HUVECs following co-transfection with miR-21 and luciferase reporters containing WT- or mut-TCONS_00024652 transcript. Data are presented as the mean ± standard deviation. \*P\<0.05 vs. control. ^\#\#^P\<0.01 vs. blank. miR-21, microRNA-21; si, small interfering; NC, negative control; Mut, mutant; WT, wild-type; HUVEC, human umbilical vein endothelial cells.](etm-16-04-3309-g02){#f3-etm-0-0-6594}

![miR-21 inhibitor reversed the suppression of HUVEC proliferation, migration and angiogenesis following TCONS_00024652 knockdown. (A) Relative expression of miR-21 in HUVECs following transfection with si-TCONS_00024652 and miR-21 inhibitor, as determined by reverse transcription-quantitative polymerase chain reaction (B) miR-21 inhibitor reversed the si-TCONS_00024652-induced inhibition of proliferation, as determined by a Cell Counting Kit-8 assay. (C) Wound healing assay was performed following transfection with si-TCONS_00024652 and miR-21 inhibitor and relative migration distance was calculated (magnification, ×200) (D) Transfected HUVECs were seeded onto Matrigel and incubated for 7 h; representative image and tube length analysis are presented (magnification, ×400). Data are presented as the mean ± standard deviation. \*P\<0.05 and \*\*P\<0.01 vs. control. ^\#^P\<0.05 and ^\#\#^P\<0.01 vs. si-TCONS_00024652-1. Si, small interfering; miR-21, microRNA-21; HUVEC, human umbilical vein endothelial cells; OD, optical density.](etm-16-04-3309-g03){#f4-etm-0-0-6594}

###### 

lcnRNA primers used in reverse transcription-quantitative polymerase chain reaction analysis.

  Name                     Sequence (5′-3′)
  ------------------------ ---------------------------
  ATG9B forward            GGTCTGCCATCTATTACTT
  ATG9B reverse            TCTACGCATTATAGTCACAA
  LncRNA-p21 forward       ATAGTAGTTGGAGACTTCA
  LncRNA-p21 reverse       ACTGTATATTCAATGTTGGC
  TCONS_00004897 forward   GGATGGCACTCCTAGTCTGC
  TCONS_00004897 reverse   GTGCAGGCCTGAGTCTTTA
  TCONS_00024652 forward   ACGCTAACTGGCACCTTGTT
  TCONS_00024652 reverse   TGGGGATTACTGGGGTAGAT
  LNC00305 forward         TAAAGGATGCGTAGGGATGG
  LNC00305 reverse         TTCATGATCACGCCCTCATA
  SENCR forward            TTTACTTTAACAGACCAGAA
  SENCR reverse            CTCCTTTGTTGAATCCAT
  MALAT1 forward           TTATCCTTGGAAGAGTATT
  MALAT1 reverse           TAAGAAGTCACATTATTGG
  ANRIL forward            TTGATGAGAAGAATAAGCC
  ANRIL reverse            CTCCTTTGATGTGTGTTT
  Tie-1AS forward          CCGGGGGTATACTACGGTC
  Tie-1AS reverse          CTCTAGAGGGGGTAGAGG
  TCONS_00004013 forward   GCGCTAACTGGCACCTTGAT
  TCONS_00004013 reverse   TTTGGATTACTGGGGTATTG
  U6 forward               GCTTCGGCAGCACATATACTAAAAT
  U6 reverse               CGCTTCACGAATTTGCGTGTCAT

MALAT1, metastasis-associated lung adenocarcinoma transcript 1; ANRIL, cyclin-dependent kinase inhibitor 2B antisense RNA 1; SENCR, smooth muscle and endothelial cell enriched migration/differentiation-associated lncRNA; tie-1AS, conserved natural noncoding antisense RNA in the tie-1 locus.
